Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 -1.88%78 EBITDA Margin % is 22.17% as of Mar. 2026, which is 31% below its 10-year median of 32.27. GuruFocus rates SHSE:605116 with a GF Score™ of 78/100 and a GF Value™ of ¥28.92 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 940 Biotechnology companies, Aurisco Pharmaceutical Co ranks better than 87.87% on this metric.
Aurisco Pharmaceutical Co (SHSE:605116) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aurisco Pharmaceutical Co EBITDA Margin % Related Terms
Aurisco Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurisco Pharmaceutical Co (SHSE:605116) has a EBITDA Margin % of 22.17% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 31% below median its historical median of 32.27. Over the past decade, Aurisco Pharmaceutical Co's EBITDA Margin % has ranged from 15.65 to 40.00. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #114 out of 940 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Aurisco Pharmaceutical Co's EBITDA Margin % too high?
Aurisco Pharmaceutical Co's current EBITDA Margin % of 22.17% is 31% below median its 10-year median of 32.27. Over the past 10 years, this metric has ranged from a low of 15.65 to a high of 40.00. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #114 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #114 out of 940 companies for EBITDA Margin %. This places Aurisco Pharmaceutical Co in the top 12% of its industry — outperforming the majority of peers. Historically, Aurisco Pharmaceutical Co's own EBITDA Margin % has ranged from 15.65 to 40.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aurisco Pharmaceutical Co and its competitors. Aurisco Pharmaceutical Co's current EBITDA Margin % is 22.17%, which is 31% below median its own 10-year median of 32.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥28.92, compared to a current price of ¥18.74 — trading 35.2% below its estimated fair value. The current EBITDA Margin % is 22.17%, which is 31% below median its 10-year median of 32.27. Aurisco Pharmaceutical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current EBITDA Margin % is 22.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.74 is trading 35.2% below its estimated GF Value™ of ¥28.92.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
EBITDA Margin %: 22.17% (31% below median its 10-year median of 32.27)
GF Value™: ¥28.92 vs. price of ¥18.74 (35.2% below fair value)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
78GF Score
Get the complete analysis for SHSE:605116
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
